Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations

Ritonavir-boosted atazanavir is an option for second-line therapy in low- and middle-income countries (LMICs). We analyzed publicly available HIV-1 protease sequences from previously PI-naïve patients with virological failure (VF) following treatment with atazanavir. Overall, 1497 patient sequences...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhee, Soo-Yon, Boehm, Michael, Tarasova, Olga, Di Teodoro, Giulia, Abecasis, Ana B., Sönnerborg, Anders, Bailey, Alexander J., Kireev, Dmitry, Zazzi, Maurizio, Shafer, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148044/
https://www.ncbi.nlm.nih.gov/pubmed/35631067
http://dx.doi.org/10.3390/pathogens11050546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148044/
https://www.ncbi.nlm.nih.gov/pubmed/35631067
http://dx.doi.org/10.3390/pathogens11050546

Ejemplares similares